Recon: White House, Senate Look to Bundle Coronavirus Bill, Stimulus Package; Novo Halts Hemophilia Studies on Safety Concerns

• Trump urges US to halt most social activity in virus fight, warns of recession (Reuters) (NYTimes)
• In Coronavirus Testing Ramp-Up, US Called Private Sector in Late (Bloomberg) (Harvard Gazette)
• White House eyes combining House bill with new coronavirus stimulus (Politico) (NYTimes)
• Mnuchin to pitch Senate GOP on third coronavirus package Tuesday (The Hill)
• San Francisco orders residents to stay home but says it's 'not a time to panic' (Reuters)
• Merck drug reduces cough frequency but taste alterations could cloud prospects (STAT) (Endpoints) (Press)
• As the market craters, Keros Therapeutics files for an IPO (STAT)
• Trump urges states to secure their own medical supplies for coronavirus (The Hill)
• Mallinckrodt loses a court case and is on the hook for $650 million in overdue Medicaid rebates (STAT)
• In another win for rival Aimmune, FDA presses pause on DBV's peanut patch with additional questions (Endpoints) (Press)
• Aimmune sees coronavirus slowing down marketing of peanut allergy therapy (Reuters)
• Before Trump’s inauguration, a warning: ‘The worst influenza pandemic since 1918’ (Politico)

• China gives go-ahead for human trials of potential COVID-19 vaccine: state media (Reuters) (Press)
• WHO urges Europe to take "boldest" actions against COVID-19 epidemic (Reuters)
• WHO calls for "change of mindset" to overcome pandemic shortages (Reuters)
• Sobering coronavirus study prompted Britain to toughen its approach (Reuters)
• Special Report: 'All is well'. In Italy, triage and lies for virus patients (Reuters)
• G7 leaders vow to do what it takes to fight coronavirus, support economies (Reuters)
• Entry into EU's Schengen zone to close - Macron (Reuters 1, 2)
• EU seeks to prevent US takeovers of coronavirus research firms (Reuters)
• CureVac says no requests to reserve production for US, scientists were not lured (Reuters)
• Coronavirus vaccine developer CureVac CEO to go on temporary medical leave (Reuters) (Endpoints) (Press)
• Global spending on drugs may hit $1.1 trillion by 2024, but the rate of growth is forecast to slow (STAT)
• Safety issues force Novo Nordisk to shutter PhIII hemophilia trials (Endpoints) (PMLive)
• AstraZeneca's Imfinzi shows sustained benefit in lung cancer study (Reuters) (Pharmafile) (Endpoints) (Fierce)
• EU Guides On ATMP Trials, Genetically Modified Cells To Be Finalized This Year (Pink Sheet-$)

• Coronavirus Is Hiding in Plain Sight (NYTimes) (Science)
• Do Antibody Testing to Understand Covid-19 (WSJ)
• Blood-Sample Shortages Slow Search for Coronavirus Drug (WSJ)
• Hopes of a coronavirus vaccine mount as three key biotech players make progress (CNBC)
• Regeneron says potential Covid-19 drugs could start human tests by early summer (STAT) (Reuters)
• Trials of potential coronavirus treatments start for some existing drugs (Reuters)
• Coronavirus Vaccine: How Hard Might Development Get? Look At Chikungunya (Pink Sheet-$)
• FDA commissioner: Be wary of anyone claiming they can cure COVID-19. Talk to your doctor. (USA Today)
• Lower death rate estimates for coronavirus, especially for non-elderly, provide glimmer of hope (STAT)
• COVID-19 Has Caused A Shortage Of Face Masks. But They're Surprisingly Hard To Make (NPR)
• A Top Cancer Hospital Faces Mask Shortages As COVID-19 Cases Show Up In Staff And Patients (Buzzfeed)
• WHO confirms two coronavirus cases among its staff (Reuters)
• German institute: Two years for pandemic to run its course (Reuters)
• Italian start-up 3D prints valves to help coronavirus patients (Reuters)
• Inside the Coronavirus Response: A Case Study in the White House Under Trump (NYTimes)
• Live tracker: How many coronavirus cases have been reported in each US state? (Politico)
• New York state coronavirus cases soar to about 1,700, hospitalizing 19% (CNBC)
• The Drug Channels Coronavirus Industry Impact Survey (Drug Channels)
• US prescription drug supply chains face coronavirus stress test (The Guardian) (Center for Biosimilars)
• In strictest US coronavirus response so far, six Bay Area counties order ‘shelter in place’ (STAT)
• A fiasco in the making? As the coronavirus pandemic takes hold, we are making decisions without reliable data (STAT)
• UK takes tougher stance to combat coronavirus, as previous approach risks hundreds of thousands of lives — study (Endpoints)
• Spain's coronavirus cases surpass 10,000, death toll rises to 491 (Reuters)
• More African countries confirm first coronavirus cases as Jack Ma pledges aid (Reuters)
• India Scrambles to Escape a Coronavirus Crisis. So Far, It’s Working. (NYTimes)
• Dutch coronavirus infections rises by 278 to 1,413, 24 deaths (Reuters)
• Austria sees coronavirus cases top 1,000, frees up funds for loan guarantees (Reuters)
• Irish PM expects 15,000 coronavirus cases by end of March (Reuters)
• France reports 21 more coronavirus deaths, raising total to 148 (Reuters)
• Philippines reports 45 new coronavirus infections (Reuters)
• Thailand reports 30 new coronavirus cases, total of 177, official says (Reuters)
• Indonesia confirms 38 more coronavirus cases, total rises to 172 (Reuters)
• Brazil Congress to seek consensus on coronavirus measures (Reuters)
• Cambodia reports 12 new cases of coronavirus, bringing total to 24 (Reuters)
• Coronavirus-hit British cruise ship finds refuge in Cuba (Reuters)
• Man in Broward County assisted living facility dies after novel coronavirus infection (Miami Herald)
• U.N. confirms 10 coronavirus cases among German refugees (Reuters)
• Portugal confirms first coronavirus death, says more to come (Reuters)
• COVID-19 Study Of Gilead’s Remdesivir Using Ebola-Style Adaptive Platform Trial (Pink Sheet-$)
• Biogen joins COVID-19 efforts with $10m support fund (PMLive)
• After Discovering a Sailor With Coronavirus, the US Navy Crowded Dozens Into One Room (ProPublica)
• Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China (JAMA)
• Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 (Nature)

• Shortcomings in the US Pharmaceutical Supply Chain (JAMA)
• Supply disruption scares and price hikes wakeup call for India to reduce dependence on China for APIs, says GlobalData (GlobalData)
• The top 10 drugs losing US exclusivity in 2020 (Fierce)
• Impact of COVID-19 on Regulatory Enforcement and Approvals (Eye on FDA)
• Biotech in the time of the coronavirus: A semi-regular column on the outbreak’s impact on drug makers (STAT)
• Children With Pneumonia Don’t Routinely Need Antibiotics (NYTimes)
• Generic ‘identity’ gets lost when companies juggle both generic and brand drugs (STAT)
• Interview with Dr. Mariana Socal on draft guidance from the FDA aimed at promoting competition in the insulin market. (FDA)
•  ‘It’s like the tortoise and the hare’: A pandemic puts Sanofi’s $600M bet to the test (Endpoints)
• Flagship’s Sigilon grabs $80M to bring Robert Langer cell therapy tech into the clinic (Endpoints)
• Newly discovered ‘magic methyl’ reaction could turbocharge the potency of some drugs (Science)
• Japan’s AGC Makes Agreed €240m Bid For MolMed (Pink Sheet-$)
• Acyclovir Availability In US May Be Affected By India Export Restrictions (Pink Sheet-$)
• Rick Klausner's Lyell partners, helps fund Eureka's work on cell therapies; Blueprint bounces higher on PhII (Endpoints)
• Temporal association between zolpidem medication and the risk of suicide: A 12-year population-based, retrospective cohort study (Nature)
• October - December 2019 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS) (FDA)

• Blue Earth Diagnostics Announces Dosing of First Patient in Phase 3 LIGHTHOUSE Clinical Trial of Targeted PET Imaging Agent rhPSMA-7.3 (18F) in Newly Diagnosed Prostate Cancer (Press)
• Lattice Biologics Ltd. Announces Initial Recruitment of Patients for a Phase 1 Clinical Trial to Access Safety and Efficacy of AmnioBoost for Treatment of COVID-19 (Press)

• Endologix secures FDA approval for new abdominal stent graft (MedtechDive)
• Intuitive Surgical among 1st big medtechs to predict costly pandemic disruptions (MedtechDive)
• Disease management firms set to capitalize on Trump admin interoperability push (MedtechDive)
• Becton Dickinson Seeks Emergency US Approval To Ramp Up Coronavirus Tests (Forbes)
• Ken Block Consulting Client Receives FDA Breakthrough Device Designation (Press)

• FDA Report Brings Hope For CBD Dietary Supplements (Law360-$)
• Conn. Judge Again Finds Pradaxa Claims Preempted (Law360-$)
• Cochlear loses appeal over $268m in patent damages (MassDevice) (Law360-$)
• Tribunal Awaits Judge's Nod On Daiichi Drug Patent Fight (Law360-$)
• Pharmacy Groups Say Scant Facts Doom Pricing Site's Suit (Law360-$)
• Drug Wholesalers Look To Derail W.Va. Bellwether Opioid Trial (Law360-$)
• Sacklers Say Major Purdue Deal Hinges On Longer Ch. 11 Stay (Law360-$)
• Medical Device Summary Judgment Win in Florida (Drug & Device Law)
• Impact of COVID-19 Pandemic on Patent Offices and Federal Courts (Patent Docs)
• FDA requires new health warnings for cigarette packages and advertisements (FDA)

• Sweden Urges Pharma To Engage In AMR Initiative (Pink Sheet-$)
• UK’s Devices Bill Can Clarify Big Data’s Health Care Potential, Says Lawyer (MedtechInsight)
• Blood bank compliance report template (MHRA)

• Hong Kong regulator will continue to recognize South Korean approvals (Emergo)

• Accredited private labs to be allowed to test for Covid-19 (Economic Times)

• Nucala approved in Canada for use in adolescents with severe eosinophilic asthma (PharmaLetter-$)

• Update on proposed clarification that certain sports supplements are therapeutic goods (TGA)